World’s biggest drug manufacturer Pfizer Inc., came to agreement on $200 million in upfront payments to Biocon for four insulin products rights.
This move is said to be increasing its border to emerging markets in diabetes portfolio.
Biocon is in the chance to profir $150 million and payments will be connected on the sales by Pfizer.
USD 200 million in a license alliance effected Read more...
tags: biocon share price, biocon, suzlon share price, yahoo india finance, biocon pfizer, glargine
No comments:
Post a Comment